SciSparc (SPRC) Total Non-Current Liabilities (2019 - 2025)
SciSparc (SPRC) posted Total Non-Current Liabilities of $222000.0 for Q4 2025, up 21.98% sequentially from $182000.0 in Q2 2025, and up 2366.67% YoY from $9000.0 in Q4 2024.
SciSparc (SPRC) Total Non-Current Liabilities (2019 - 2025) Analysis & Trends
SciSparc has reported Total Non-Current Liabilities for 7 years, with the latest figure at $222000.0 in Q4 2025.
- Quarterly Total Non-Current Liabilities rose 2366.67% year-over-year to $222000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $222000.0 (up 2366.67% YoY) and the FY2025 annual result came in at $222000.0, up 2366.67% from the prior year.
- Total Non-Current Liabilities improved to $222000.0 in Q4 2025 per SPRC's latest filing, from $182000.0 in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $6.0 million in Q4 2023 and troughed at $9000.0 in Q4 2024.
- A 5-year average of $3.0 million and a median of $4.2 million in 2022 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2024 and 2025: Total Non-Current Liabilities tumbled 99.85% in 2024, then surged 2366.67% in 2025.
- Over 5 years, Total Non-Current Liabilities stood at $4.7 million in 2021, then gained by 14.58% to $5.4 million in 2022, then increased by 10.66% to $6.0 million in 2023, then sank by 99.85% to $9000.0 in 2024, then soared by 2366.67% to $222000.0 in 2025.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $222000.0, $182000.0, and $9000.0 for Q4 2025, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.32 Bn |
| 10 | SciSparc | 831,418.60 | 831,418.60 | - | 222,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 222,000.00 |
| Jun 30, 2025 | 182,000.00 |
| Dec 31, 2024 | 9,000.00 |
| Jun 30, 2024 | 26,000.00 |
| Dec 31, 2023 | 5.99 Mn |
| Jun 30, 2023 | 4.70 Mn |
| Dec 31, 2022 | 5.42 Mn |
| Sep 30, 2022 | 5.26 Mn |
| Jun 30, 2022 | 4.17 Mn |
| Dec 31, 2021 | 4.73 Mn |
| Jun 30, 2021 | 2.09 Mn |
| Dec 31, 2020 | 354,000.00 |
| Jun 30, 2020 | 598,000.00 |
| Dec 31, 2019 | 101,000.00 |
| Jun 30, 2019 | 602,000.00 |